@article{3092292, title = "Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma", author = "Katsoulidou, A and Papachristou, E and Petrodaskalaki, M and Sypsa, V and and Anastassopoulou, CG and Gargalianos, P and Karafoulidou, A and and Lazanas, M and Kordossis, T and Andoniadou, A and Hatzakis, A", journal = "Journal of Virological Methods", year = "2004", volume = "121", number = "1", pages = "93-99", publisher = "ELSEVIER SCIENCE BV", issn = "0166-0934", doi = "10.1016/j.jviromet.2004.06.007", keywords = "HIV-1 RNA; viral load; LCx; branched DNA; COBAS Amplicor Monitor v1.5", abstract = "The LCx HIV RNA quantitative assay (Abbott Laboratories, Delkenheim, Germany) was compared with the Versant HIV-1 RNA 3.0 (bDNA) assay (Bayer, Tarrytown, NY) and the COBAS Amplicor HIV-1 Monitor v1.5 test (Roche Diagnostics, Branchburg, NJ), using plasma samples of various viral load levels from HIV-1-infected patients. Considering the lower limit of the linear range of 50 copies/ml of both assays, the detection range of the LCx was 127/151 (84.1%) versus the 131/151 (86.8%) of the bDNA 3.0 assay, while overall agreement between the two assays was 93.4% (141/151). LCx and bDNA 3.0 results were found to be strongly correlated (r = 0.96). The fitted regression line was described by the equation log(10)(LCx copies/ml) = 0.05 + 1.06 x log(10)(bDNA 3.Ocopies/ml) with 95% CI for the estimated slope and intercept at 1.01, 1.12 and -0.16. 0.26, respectively. Similarly, the detection range of the LCx was 115/148 (77.7%) versus the 128/148 (86.5%) of the Monitor v 1.5 test. A 91.2% concordance (135/148) was observed between these two assays at a cut-off of 50 copies/ml. LCx and Monitor v 1.5 results were highly correlated (r = 0.96). The fitted regression line was described by the equation log(10)(LCx copies/ml)=0.06 + 1.03 x log(10)(Monitor v1.5 copies/ml) with 95% Cl for the estimated slope and intercept at 0.97, 1.09 and -0.16, 0.28, respectively. (C) 2004 Elsevier B.V. All rights reserved." }